GAMMA Investing LLC Increases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

GAMMA Investing LLC lifted its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 6,279.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,049 shares of the biopharmaceutical company's stock after purchasing an additional 26,625 shares during the quarter. GAMMA Investing LLC's holdings in Ultragenyx Pharmaceutical were worth $979,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Van ECK Associates Corp boosted its position in Ultragenyx Pharmaceutical by 18.4% during the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after buying an additional 273 shares during the period. State of New Jersey Common Pension Fund D boosted its holdings in Ultragenyx Pharmaceutical by 33.8% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 46,514 shares of the biopharmaceutical company's stock valued at $1,957,000 after acquiring an additional 11,745 shares during the period. Principal Financial Group Inc. grew its position in Ultragenyx Pharmaceutical by 4.1% during the 4th quarter. Principal Financial Group Inc. now owns 89,955 shares of the biopharmaceutical company's stock worth $3,784,000 after acquiring an additional 3,515 shares during the last quarter. Human Investing LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter worth approximately $42,000. Finally, Peregrine Capital Management LLC lifted its position in Ultragenyx Pharmaceutical by 22.1% in the fourth quarter. Peregrine Capital Management LLC now owns 163,888 shares of the biopharmaceutical company's stock valued at $6,895,000 after purchasing an additional 29,684 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors.

Ultragenyx Pharmaceutical Stock Down 0.8%

Shares of NASDAQ RARE traded down $0.31 during midday trading on Friday, hitting $37.05. The stock had a trading volume of 526,890 shares, compared to its average volume of 837,573. The business's 50 day moving average is $36.37 and its 200-day moving average is $39.79. Ultragenyx Pharmaceutical Inc. has a 52 week low of $29.59 and a 52 week high of $60.37. The company has a market cap of $3.50 billion, a P/E ratio of -6.30 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same period last year, the company posted ($2.03) earnings per share. The business's revenue was up 28.0% compared to the same quarter last year. As a group, analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on RARE. Guggenheim reiterated a "buy" rating and set a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday. William Blair started coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Piper Sandler reduced their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Morgan Stanley increased their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $87.00.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.